SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-21-145678
Filing Date
2021-04-30
Accepted
2021-04-30 17:20:04
Documents
4
Period of Report
2021-06-25

Document Format Files

Seq Description Document Type Size
1 DEF 14A d240505ddef14a.htm DEF 14A 329332
2 GRAPHIC g240505dsp049.jpg GRAPHIC 247839
3 GRAPHIC g240505dsp050.jpg GRAPHIC 142676
4 GRAPHIC g240505g25a66.jpg GRAPHIC 80488
  Complete submission text file 0001193125-21-145678.txt   974844
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39676 | Film No.: 21879877
SIC: 2836 Biological Products, (No Diagnostic Substances)